# Cullinan Therapeutics Inc. (CGEM) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $15.75, market value $968 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Cullinan Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 3.1×**. The shares trade at 3.1× book value; book value is a meaningful part of the valuation.

## Profitability
- **Return on equity: -53.8%**. Return on equity is negative because earnings are negative.
- **Return on assets: 24.8%**. Each dollar of assets produces 24.8% of profit.

## Financial health
- **Current ratio: 10.25** (quick 10.25). Current assets cover the next year's liabilities 10.25 times.

## Dividends
- **Dividend: none**. Cullinan Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (10 analysts). 10 analysts cover Cullinan Therapeutics Inc.; the consensus is strong_buy, with an average price target of $34.60 (+120% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 72.4%** (YTD 44.3%, 3-mo -8.1%). The shares are up 72.4% over twelve months including dividends.
- **From 52-week high: -32.1%** (134.0% above the low). Trading 32% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 45**. An RSI of 45 is neutral.
- **Beta (1 yr): 1.54** (volatility 80%). Beta of 1.54 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CGEM · Page: https://foliofundamentals.com/stocks/cgem

Not investment advice.